Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer [0.03%]
MK-1775和CUDC-907协同抑制前列腺癌的作用及机制研究
Saisai Ma,Yichen Xu,Minmin Liu et al.
Saisai Ma et al.
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatment of prostate cancer, and it is urgent to explore an innovative therapeutic strategy. MK-1775, a highly selective WEE1...
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial [0.03%]
雷利雅脑转移试验：雷莫芦单抗联合厄洛替尼或奥希替尼治疗无症状脑转移的EGFR突变NSCLC患者的疗效：分子生物标志物的见解
Hiroyasu Kaneda,Haruko Daga,Asuka Okada et al.
Hiroyasu Kaneda et al.
Background: The RELAY-Brain trial examined the clinical utility and survival impacts of ramucirumab (RAM) combined with epidermal growth factor receptor (EGFR)-TKI in patients with EGFR-mutated non-small-cell lung cancer ...
Linifanib alone and in combination with metronomic chemotherapy is active on cutaneous T-cell lymphoma cells by targeting the AKT/mTOR signaling pathway [0.03%]
仑伐替尼及其小剂量化疗联合应用通过作用于AKT/mTOR信号通路对皮肤t细胞淋巴瘤有效
Marta Banchi,Maria Christina Cox,Arianna Bandini et al.
Marta Banchi et al.
Cutaneous T-cell lymphomas (CTCLs) are a rare and heterogeneous subset of skin-localized, non-Hodgkin lymphomas. Our aim was to evaluate the in vitro antitumor activity of the multi-kinase inhibitor linifanib, either alone or in combination...
Dual PTCH2 mutation [Ser391*, Leu104Pro]: unveiling a potential new genetic susceptibility factor for glioma development [0.03%]
PTCH2基因双重突变[Ser391*，Leu104Pro]：揭示了胶质瘤发病的潜在新遗传易感因素
Xiang Li,Yingting Wu,Tiantian Han et al.
Xiang Li et al.
Gliomas are a heterogeneous type of central nervous system tumor. The etiology of glioma formation remains elusive, with approximately 5% of gliomas being familial, underscoring the significance of understanding genetic susceptibility in gl...
Stage-specific efficacy of osimertinib in treatment-naïve EGFR-mutant non-small cell lung cancer according to baseline genetic alterations in circulating tumor DNA [0.03%]
奥希替尼一线治疗携带不同基线突变的EGFR突变阳性非小细胞肺癌患者的疗效：AENEAS研究的循环肿瘤DNA亚组分析
Yoshihiko Taniguchi,Akihiro Tamiya,Mitsuo Osuga et al.
Yoshihiko Taniguchi et al.
The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation...
Investigation of the association between therapeutic effectiveness of anamorelin and Glasgow prognostic score in patients with cancer cachexia: a competing risk analysis [0.03%]
安莫雷林治疗癌症恶病质疗效与GPS评分关联性分析及竞争风险模型列线图预测效能研究
Kazuhiro Shimomura,Takatsugu Ogata,Akimitsu Maeda et al.
Kazuhiro Shimomura et al.
Anamorelin, a highly selective ghrelin receptor agonist, enhances appetite and increases lean body mass in patients with cancer cachexia. However, the predictors of its therapeutic effectiveness are uncertain. This study aimed to investigat...
The analysis of molecular classification of pulmonary neuroendocrine tumors and relationship between YAP1 and efficacy [0.03%]
肺神经内分泌肿瘤的分子分型及YAP1与疗效关系分析
Meihui Li,Xinyuan Wang,Jiali Gong et al.
Meihui Li et al.
A novel molecular classification for small cell lung cancer (SCLC) has been established utilizing the transcription factors achaete-scute homologue 1 (ASCL1), neurogenic differentiation factor 1 (NeuroD1), POU class 2 homeobox 3 (POU2F3), a...
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study [0.03%]
仑伐替尼联合免疫治疗与仑伐替尼单药治疗难治性不可切除肝细胞癌患者的疗效：回顾性研究
Zeyu Yu,Bin Leng,Ran You et al.
Zeyu Yu et al.
Purpose: The combination therapy of lenvatinib and immunotherapy as first-line treatment remains controversial in unresectable hepatocellular carcinoma (uHCC). This research aimed to compare the efficacy and safety of len...
Efficacy and safety of multi-target tyrosine kinase inhibitor AL2846 combined with gemcitabine in pancreatic cancer [0.03%]
多靶点激酶抑制剂AL2846联合吉西他滨治疗胰腺癌的疗效与安全性研究
Rui Liu,Zhi Ji,Xia Wang et al.
Rui Liu et al.
Pancreatic cancer patients urgently need new treatments, and we explored the efficacy and safety of combination therapy with AL2846 and gemcitabine in pancreatic cancer patients. This was a single-arm, single-center, open-label phase I/IIa ...
Clinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis [0.03%]
帕博利珠单抗致斯蒂文斯-约翰逊综合征/中毒性表皮坏死松解症的临床特征、治疗及预后
Zhaoquan Wu,Xiting Li,Rui Huang et al.
Zhaoquan Wu et al.
The understanding of pembrolizumab-induced Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN) primarily derives from case reports, leaving specific clinical features largely unknown. This study aims to investigate the clinical...